**Introduction** Carotid artery stenting (CAS) has evolved as an alternative treatment for carotid artery disease. In most patients, the indication for carotid intervention has been based on neurological symptoms in combination with the degree of stenosis in the ipsilateral carotid artery. Recently, the role of timing of revascularization in the prevention of recurrent stroke in symptomatic patients has gained interest. CREST (Carotid Revascularization Endarterectomy versus Stenting Trial) reported the shortest median interval; this was still 22 days for CEA and 18 days for CAS. Because of the high risk of early stroke recurrence after plaque rupture, it is now accepted that intervention offers the greatest benefit when performed soon after the onset of neurological symptoms.

**Methods** Data were analyzed for early carotid stenting, patients who had a stroke as a presenting complaint were only chosen for this study. Thirty cases were identified between Oct 2015 and Feb 2021, that had a stroke and associated with severe carotid disease in the same vascular territory as the stroke. A statistical analysis was performed to reveal interesting data. Out of the 30 patients, 1 patient (3.3%) had an intraparenchymal hemorrhagic conversion in the stroke vascular area, 1 patient (3.3%) had a periprocedural subarachnoid hemorrhage, 1 patient (3.3%) had a reperfusion injury and developed seizures, and 1 patient (3.3%) had a new stroke. The mean time to perform carotid stenting was 2.6 days, median was 2 days.

**Conclusion** Early carotid stenting should be considered, when waiting 4-6 weeks might not be a feasible option due to high risk of recurrent stroke. The rate of complications is lower than what has been published in case reports and metaanalyses in the literature, likely due to improved periprocedural management of platelet activity and blood pressure. Our data suggest that early carotid stenting is feasible and should be considered an option in selected cases. Larger data sets will need to be analyzed to get a clear idea of the overall complication rate.

**REFERENCES**


Disclosures S. Bhatt: None. M. Colasurdo: None. K. Raghuram: None.

**E-141 CT ANGIOGRAPHY IN PATIENTS PRESENTING WITH LOWER NIH STROKE SCALES**

*M Elshikh, S Bhatt*, M Colasurdo, O Ezzeldin, A Al Taweele, A Morshid, B Miles, K Raghuram. 1Department of Radiology, UTMB, Galveston, TX; 2Department of Neurology, UTMB, Galveston, TX; 3School of Medicine, UTMB, Galveston, TX

10.1136/neurintsurg-2021-SNIS.236

**Introduction** Mechanical thrombectomy (MT) is the standard-of-care treatment for patients with ischemic stroke (IS) with proximal large intracranial vessel occlusion within 6 hours from onset of symptoms. More than half of those who receive tPA for a M2 occlusion still do not achieve adequate recanalization. M2 IS may have a low growth rate of infarct volume and smaller final infarct volumes than found with main MCA trunk infarctions, but can be just as disabling, particularly if language centers are involved. The ideal selection criteria for MT in patients with M2 occlusions remain controversial, which leads to heterogeneous practice patterns among stroke specialists. We analyzed M1 and M2 strokes who underwent MT and their CT perfusion (CTP) data.

**Method** We first analyzed 34 patients CTP data, 17 each with M1 and M2 strokes and compared their NIH stroke scales and their CBF < 30% (core) and Tmax > 6 seconds (hypoperfused). As expected, we found that M1 strokes have a larger ischemic core and a larger hypoperfused area than M2 strokes (CBF > 30 for M1 was 46.5, while CBF > 30 for M2 was 5.9, p < 0.05. Tmax > 6 for M1 was 132.4, while Tmax > 6 for M2 was 31.6, (p < 0.05). Also, we found that M2 stroke were less likely to present with a CBF defect (78% of M1 patients with mean CBF defect of 46.5 +/- 15.0 and 35% of patients with M2 defect with mean CBF defect of 5.9 +/- 3.4) Although, their NIH scores didn’t reveal a statistical difference (NIH for M1 was 14.0, while NIH for M2 was 8.5, p = 0.07.)

Next, we analyzed the relationship between M2 strokes with NIH stroke scales of less than and greater than 6, and the Tmax > 6 defect volume associated.

There was no trend which could be correlated with Tmax > 6 volume with increase in NIHSS (p=0.4). The average Tmax volume for patients with M2 defect was analyzed and found to be between 0 - 87 with a mean of 31.6 +/- 6.71% of M2 lesions presented with an ischemic (Tmax > 6) volume of 44 ml at risk which could potentially be considered for endovascular treatments.

We found NIH < 6 was statistically not different than NIH >= 6 (NIH < 6 was 20.7 while NIH >= 6 was 41.3, p 0.14)

**Conclusion** CTP should be ordered for patients presenting with strokes with NIH < 6. Also, Boned et al. showed that CTP overestimated infarct core for more than 10 mL in 38% of the patients. Choosing not to proceed with CT angiography based on CTP and NIH stroke scale-based patient selection may deny treatment to patients who might benefit from reperfusion therapy. 71% of M2 strokes present with Tmax > 6 of 44ml which could potentially be considered for endovascular treatments.